Affordable Access

Immunotherapeutic strategies for high-risk bladder cancer.

Authors
  • Sharma, Padmanee
  • Old, Lloyd J
  • Allison, James P
Type
Published Article
Journal
Seminars in Oncology
Publisher
Elsevier - WB Saunders
Publication Date
Apr 01, 2007
Volume
34
Issue
2
Pages
165–172
Identifiers
PMID: 17382800
Source
Medline
License
Unknown

Abstract

Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-grade superficial disease. The nonspecific immune modulation that occurs as a result of BCG therapy is not well understood; however, the success of BCG therapy provides a basis for the exploration of mechanisms related to immune responses and the development of novel immunotherapeutic agents for the treatment of high-risk disease. In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer.

Report this publication

Statistics

Seen <100 times